Skip to content

MOBY® keeps life moving.

Nurse pushing a child in a MOBY pod outside a hospital
The world's first mobile protective pod. CE marked under EU MDR. In clinical use.

Human connection is our most essential superpower. MOBY is created to secure freedom and human contact, even in the most precarious of medical situations. Because together, we get better.

Clinicians' first choice.

Enhancing quality of life

Human connection is vital for patient recovery. By enabling safe, close, and clear interaction, MOBY fosters a supportive healing environment—even under isolation protocols.

Improved patient safety

Designed to prevent cross-contamination and minimize risks during transport, MOBY prioritizes patient well-being and peace of mind.

More effective routines

Relieves pressure on patients and professionals by reducing impossible choices between human connection and safety.

Protecting what matters most.

MOBY is a mobile protective pod. It surrounds the patient with a filtered, pressure-controlled environment that travels with them, so they can leave the room. Positive pressure for the immunocompromised patient, negative pressure for the infectious one.

Developed with the clinicians who use it.

“We want MOBY to be available wherever a child needs a transplant. For our patients, it is a real and lasting improvement in their care.”

Prof. Dr. med. Hedwig Deubzer
Prof. Dr. med. Hedwig Deubzer
Director of Pediatric Oncology and Hematology, Charité Berlin

“I hope that the use of MOBY for immunocompromised children with cancer will be an important step towards breaking the burdening isolation of our patients.”

Prof. Dr. med. Angelika Eggert
Prof. Dr. med. Angelika Eggert
Chair of the Executive Board, Universitätsmedizin Essen

“As Sphaira's clinical partner, we are delighted to help shape the development of MOBY. With it, visits to our facilities become possible regardless of the infection situation. At the same time, we expect MOBY to fundamentally improve the daily lives of patients in protective isolation. I believe that human contact between patients and their families supports healing and leads to better outcomes. That is what we expect from MOBY, too.”

Prof. Dr. med. Dr. phil. Martin Ebinger
Prof. Dr. med. Dr. phil. Martin Ebinger
Medical Director, Head of Neurology, Medical Park Berlin Humboldtmühle

Clinical partners

CE marked. Deployed. Under study.

In clinical use

Charité – Universitätsmedizin Berlin

Clinical study

Prospective cohort study at Charité Berlin on quality of life in pediatric patients with severe immunosuppression.

Follow-up studies

Investigator-initiated multicenter study in planning. Pilot study in the United States in drafting.

EU Regulatory

CE-marked medical device under EU MDR 2017/745.

United States

In active dialogue with the U.S. FDA. Not available for sale in the United States.

Built for the strictest isolation protocols.

Wherever isolation prohibits movement or seeing loved ones, MOBY belongs.

Stem cell transplantation

Leave the room without leaving protection.

Solid organ transplantation

Protected mobility during induction immunosuppression.

Severe burns

Protected transport and protected visits.

Pediatric oncology

Time outside the room for children in prolonged neutropenia.

Acute myeloid leukemia

Induction and consolidation without weeks behind a door.

Palliative care

Contact and movement when they matter most.

Source isolation

The hospital stays protected while the patient moves.

The best way through is together.

Nurse in scrubs and mask in a hospital corridor

Whether you run a transplant unit, lead hospital hygiene, or bring medical technology to a new market, we would like to talk.